Navigation Links
Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Date:6/2/2009

p>

Presentation Title: Weight Loss with VI-0521 (Qnexa) Stops Progression Towards Type 2 Diabetes in Obese Non-Diabetic Subjects

Abstract: 119-OR

Location: Louisiane C, Morial Convention Center

Presenter: Louis J. Aronne, MD

Date and Time: Monday, June 8, 2009, 4:30-6:30 P.M.

Session: New Treatments in Development

Presentation Title: One Year Treatment with VI-0521(Qnexa) in Type 2 Diabetes Demonstrates Continued Glycemic Improvement and Weight Loss

Abstract: 361-OR

Location: Hall E-2, Morial Convention Center

Presenter: W. Timothy Garvey, MD

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are b
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
6. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
7. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
8. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
9. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
10. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
11. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 Best Sanitizers, ... for the food processing industry, is asking industry professionals ... side comparison of the E2 soap they’re currently using ... Foam Soap . Hand hygiene is critical to ... food processing environment. Six key criteria are identified to ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... new market research report is ... Whole Exome Sequencing Market ... Preparation, Target Enrichment), by Services ... Synthesis), by Application (Cancer, Monogenic ...
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
(Date:8/28/2014)... August 28, 2014 PrimeSource Building ... materials, selected SoundConnect to support their ... based audio and web conferencing platform GlobalMeet powered ... PrimeSource’s employees’ needs. SoundConnect delivers award winning ... PrimeSource Building Products will be utilizing GlobalMeet ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3PrimeSource Chooses SoundConnect as Collaboration Provider 2
... bit proprietary about the companies that have launched products at the ... always sorry when a company hits the bumps that inevitably pock ... so many of my "children" see the rewards for their very ... on the fund-raising circuit. Jingle Networks (DEMOfall 05) has ...
... days of Marco Polo, if not well before. It started ... to finished products. Next came financial capital. In more recent ... have gone global. What's different today from the past is ... perceived opportunities are vast but there are downsides as well, ...
... after solidifying its global market position with a key acquisition, ... working capital as well. The company announced that it will ... sources. , ,Imago, a provider of atom probe tomography instruments ... with funding led by Draper Fisher Jurvetson (DFJ), ...
Cached Biology Technology:A windfall of funds for DEMO companies 2A windfall of funds for DEMO companies 3Learning to swim in the global talent pool 2Learning to swim in the global talent pool 3Learning to swim in the global talent pool 4Investors commit $3.4 million to Imago 2
(Date:8/28/2014)... assigned a number of 435-million-year-old fossils to a ... in shallow marine habitats and were far less ... , Before they sank to the bottom ... some 435 million years ago, these arthropods preyed ... although they were not exactly inconspicuous, possessing a ...
(Date:8/27/2014)... big step in understanding the mysteries of the human ... analyses that provide the most detailed comparison yet of ... human function. , The research, appearing August 28 ... the information encoded in the three species, genomes is ... organized into chromosomes. , The results add billions of ...
(Date:8/27/2014)... effective doses of the HIV drug maraviroc, a new ... completed before the drug was licensed in 2007, included ... key to removing maraviroc from the body. The current ... protein including nearly half of African-Americans end ... those who lack the protein even when given the ...
Breaking Biology News(10 mins):Paleontology: Oldest representative of a weird arthropod group 2Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4Dosage of HIV drug may be ineffective for half of African-Americans 2
... Questions about the existence of life in outer space may ... Houston professor. , Understanding how life evolved on Earth is ... universe one might find life and what it might be ... and biochemistry. Fox is finishing work on a three-year research ...
... of one family of antibiotics kill bacteria that make ... developers make slight changes to these antibiotics to make ... Irina Artsimovitch, a study co-author and an assistant professor ... studied belong to the rifamycin family. Until now, researchers ...
... to seven million years ago, when the lineage of ... rutabagas and turnips may have been one of the ... the University of Minnesota and Richard Wrangham of Harvard ... roots and tubers must have sustained our ancestors who ...
Cached Biology News:Evolution of life on Earth may hold key to finding life in outer space 2Evolution of life on Earth may hold key to finding life in outer space 3Researchers find how some antibiotics kill bacteria 2Researchers find how some antibiotics kill bacteria 3“Hitchhiking?Viruses as Cancer Drug Delivery System 2
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
... Unique, compact measuring instrument for calibrating ... compact design and the robust carrying case, ... both in the laboratory and on-site at ... easy to use because the individual channels ...
... ChIP-on-chip Microarray is specifically designed for ... DNA binding proteins by pairing chromatin ... This set delivers robust hybridization and ... binding events and fewer false positives. ...
... Whole Genome ChIP-on-chip Microarray is specifically ... (S. cerevisiae) DNA binding proteins by ... DNA microarrays. This set delivers robust ... greater true binding events and fewer ...
Biology Products: